Johnson & Johnson: Number of Employees 2006-2019 | JNJ

Interactive chart of Johnson & Johnson (JNJ) annual worldwide employee count from 2006 to 2019.
  • Johnson & Johnson total number of employees in 2019 was 132,200, a 2.15% decline from 2018.
  • Johnson & Johnson total number of employees in 2018 was 135,100, a 0.82% increase from 2017.
  • Johnson & Johnson total number of employees in 2017 was 134,000, a 6.01% increase from 2016.
  • Johnson & Johnson total number of employees in 2016 was 126,400, a 0.55% decline from 2015.
Johnson & Johnson Annual Number of Employees
2019 132,200
2018 135,100
2017 134,000
2016 126,400
2015 127,100
2014 126,500
2013 128,100
2012 127,600
2011 117,900
2010 114,000
2009 115,500
2008 118,700
2007 119,200
2006 122,200
2005 115,600
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $345.705B $82.059B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $277.843B 0.00
Merck (MRK) United States $195.141B 14.82
Novartis AG (NVS) Switzerland $188.959B 15.73
Pfizer (PFE) United States $181.075B 11.06
Novo Nordisk (NVO) Denmark $142.554B 24.47
Eli Lilly (LLY) United States $132.760B 22.97
Bristol-Myers Squibb (BMY) United States $125.834B 11.94
AstraZeneca (AZN) United Kingdom $117.205B 25.23
AbbVie (ABBV) United States $112.508B 8.52
Sanofi (SNY) France $109.481B 13.01
GlaxoSmithKline (GSK) United Kingdom $94.546B 11.99
Bayer (BAYRY) Germany $53.976B 7.78
H Lundbeck (HLUYY) Denmark $5.923B 10.29
Innoviva (INVA) United States $1.191B 8.22